FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
Visual Abstract. Overall survival for patients treated with salvage radiotherapy: real world data from an entire country. A patient with biochemical recurrence after radical prostatectomy and no ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Socio-economic disparities in prostate cancer hospitalizations and outcomes across the United States. Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC) ...
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
Add Yahoo as a preferred source to see more of our stories on Google. Buckingham Palace officials revealed that King Charles III has been diagnosed with cancer. Last month, the king, 75, underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results